{"id":675090,"date":"2023-11-03T16:46:02","date_gmt":"2023-11-03T16:46:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=675090"},"modified":"2023-11-03T16:46:02","modified_gmt":"2023-11-03T16:46:02","slug":"marginal-zone-lymphoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-abbvie-adicet-bio-arqule-merck-beigene-bayer","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/marginal-zone-lymphoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-abbvie-adicet-bio-arqule-merck-beigene-bayer_675090.html","title":{"rendered":"Marginal Zone Lymphoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Adicet Bio, ArQule, Merck, BeiGene, Bayer"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Marginal Zone Lymphoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Adicet Bio, ArQule, Merck, BeiGene, Bayer\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Marginal Zone Lymphoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Adicet Bio, ArQule, Merck, BeiGene, Bayer\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Marginal Zone Lymphoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Marginal Zone Lymphoma Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Marginal Zone Lymphoma Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Marginal Zone Lymphoma Pipeline report embraces in-depth commercial, regulatory, and Marginal Zone Lymphoma clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Marginal Zone Lymphoma drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/marginal-zone-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Marginal Zone Lymphoma Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for Marginal Zone Lymphoma treatment and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different Marginal Zone Lymphoma therapies segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the major Marginal Zone Lymphoma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the Marginal Zone Lymphoma drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Marginal Zone Lymphoma therapeutic market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/d61fb50d56386feed4d647aa4d83f9a4.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Marginal Zone Lymphoma Companies Actively Working in the Therapeutic Market Include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">AbbVie, ADC Therapeutics, Adicet Bio, Inc, ArQule, ArQule\/Merck, Astrazeneca, Bayer, BeiGene, Beijing Mabworks Biotech Co., Ltd., Bio-Path Holdings, Inc., Boryung Pharmaceutical Co., Ltd, Bristol-Myers Squibb, Celgene Corporation, Celldex Therapeutics, Cellectar Biosciences, Inc., ENTEROME SA, Genentech, Inc., Genmab, Gilead Sciences, HUTCHMED, IGM Biosciences, Inc., Incyte Corporation, InnoCare Pharma, Innovent Biologics, Kite Pharma, Loxo Oncology, MEI Pharma, Inc., Merck KGaA, NantKwest\/ImmunityBio, Newave Pharmaceutical Inc, Nordic Nanovector, Novartis, Nurix Therapeutics, Inc., Oncternal Therapeutics, Inc, Roche Pharma, Sound Biologics, TG Therapeutics, Inc., TriSalus Life Sciences, VelosBio Inc., Verastem\/Secura Bio, and others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging and Marketed Marginal Zone Lymphoma Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Amdizalisib (HMPL-689): HUTCHMED<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Betalutin : Nordic nanovector<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Calquence : AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">EO2463: Enterome<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Orelabrutinib: InnoCare Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tafasitamab: Incyte Corporation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Yescarta: Gilead Sciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Zandelisib: MEI Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Revlimid (lenalidomide) + rituximab: Celgene Corporation\/Bristol-Myers Squibb<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Imbruvica (ibrutinib): AbbVie, Janssen Biotech, Pharmacyclics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Umbralisib: TG Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many More<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Marginal Zone Lymphoma Companies Working in the Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/marginal-zone-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/marginal-zone-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Marginal Zone Lymphoma Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers the emerging products under different phases of clinical development like &#8211;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued and inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inhalation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inhalation\/Intravenous\/Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intranasal<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous\/ Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral\/intranasal\/subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Antisense oligonucleotides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunotherapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Protein<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Recombinant protein<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Stem Cell<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Vaccine<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Marginal Zone Lymphoma Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/marginal-zone-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/marginal-zone-lymphoma-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Table of Content (TOC)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Marginal Zone Lymphoma Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Marginal Zone Lymphoma &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Marginal Zone Lymphoma Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Marginal Zone Lymphoma Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Marginal Zone Lymphoma Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Marginal Zone Lymphoma Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Marginal Zone Lymphoma Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Major Marginal Zone Lymphoma Companies in the Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Marginal Zone Lymphoma Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Marginal Zone Lymphoma Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Marginal Zone Lymphoma Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Marginal Zone Lymphoma Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/marginal-zone-lymphoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/marginal-zone-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/mucinous-cystic-neoplasms-mcns-market\">Mucinous Cystic Neoplasms (MCNs) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&#8220;Mucinous Cystic Neoplasms (MCNs) Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Mucinous Cystic Neoplasms market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Mucinous Cystic Neoplasms market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=marginal-zone-lymphoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-abbvie-adicet-bio-arqule-merck-beigene-bayer\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=marginal-zone-lymphoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-abbvie-adicet-bio-arqule-merck-beigene-bayer\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Marginal Zone Lymphoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/marginal-zone-lymphoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-abbvie-adicet-bio-arqule-merck-beigene-bayer_675090.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,417,406,404],"tags":[],"class_list":["post-675090","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=675090"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675090\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=675090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=675090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=675090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}